ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

nalmefene

Also written as “Nalmefene”, “Nalmefene hydrochloride” and “Nalmefene + 0.94% MgCl2”.

Its studies are mostly in Alcoholism · Opiate Overdose · Pruritus · Renal Insufficiency · Smoking Cessation, led by 7 companies.

Drug pageNalmefene: every studyMany companies study it; this page follows only the 20 they lead. All 35 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jul 17, 201420 company-led studies, 1 open or runningNext primary completion: Mar 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
H. Lundbeckits history only60 open or runningphase 4since Jul 17, 2014Dec 18, 2008none ahead
Indivior Pharmaceuticalsits history only30 open or runningphase 1since Feb 15, 2021Feb 15, 2021none ahead
Knoa Pharmaits history only30 open or runningphase 4since Mar 15, 2023Mar 15, 2023none ahead
Otsukaits history only30 open or runningphase 3since Feb 10, 2015Feb 10, 2015none ahead
Somaxon Pharmaceuticalsits history only20 open or runningphase 3since Aug 17, 2005Aug 17, 2005none ahead
Tharimmuneits history only21 open or runningphase 2since Dec 3, 2024Dec 27, 2023Mar 1, 2027phase 2 · NCT06733519
Serentis10 open or runningphase 2since Feb 5, 2009Feb 5, 2009none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 5, 2009First study: phase 2 study in PruritusFirst studyNCT00838708 · 62 enrolled · United States

TargetBeta

“Mu opioid receptor antagonist; Delta opioid receptor antagonist; Kappa opioid receptor partial agonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
Naltrexoneruleorexigen-therapeutics-incphase 442
NalbuphineruleTrevi Therapeuticsphase 421
cebranopadolruleTris Pharmaphase 318

Studies

The one study Serentis leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00838708Pruritus · United States2CompletedJul 200962

How it is read

Names in the registry

  • “Nalmefene”, 5 entries
  • “Nalmefene hydrochloride”, 3 entries
  • “Nalmefene + 0.94% MgCl2”, 2 entries
  • “Nalmefene Hydrochloride”, 2 entries
  • “nalmefene”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.